Oral anticoagulation (OAC) is highly effective in preventing ischemic strokes in patients with
atrial fibrillation (AF) and conveys a clear net clinical benefit despite a potential risk for major …

Dabigatran is a novel direct thrombin inhibitor that has recently been approved for primary
and secondary stroke prevention and prevention of systemic embolism in patients with atrial …

Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Dabigatran was expected to replace warfarin for stroke prevention in patients with
nonvalvular atrial fibrillation (AF) who are warfarin naive, difficult to maintain in therapeutic …

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Introduction: The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY)
trial demonstrated dabigatran (150mg) to be superior to warfarin for stroke prevention in …

See related research article by Xu and colleagues in CMAJ Open at www. cmajopen.
ca/content/1/3/E115 control were consistent for the primary efficacy outcome of stroke or …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Background Warfarin has been the predominant anticoagulant for the prevention of stroke
and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). Its …